GlassScriptPhysician profile
Katherine Dorman
NPI 1336601210
$3,786.05
in general payments reported to CMS, 2019-2025
34 companies · $770 in 2025
The $770 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,425 · 2022: $698 · 2023: $439 · 2024: $455 · 2025: $770.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,647 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.13 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $388.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $303.25 | 2021-2025 | Farxiga, Airsupra, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.55 | 2021-2025 | Jardiance |
| Abbvie INC. | $221.71 | 2021-2024 | |
| Pfizer INC. | $217.86 | 2021-2025 | |
| Glaxosmithkline, LLC. | $195.98 | 2021-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $175.19 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $175.19 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $158.01 | 2021-2023 | Xifaxan |
| Abbott Laboratories | $151.63 | 2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $144.54 | 2024-2025 | Korlym |
| Amgen INC. | $138.50 | 2021-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $138.26 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $122.21 | 2021 | |
| Novo Nordisk INC | $117.83 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.77 | 2025 | Caplyta |
| Nestle Healthcare Nutrition INC. | $97.20 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.45 | 2021-2023 | Gattex |
| Merck Sharp & Dohme LLC | $79.76 | 2021-2023 | Dificid |
| Aimmune Therapeutics, INC. | $74.74 | 2024-2025 | Zenpep |
| Esperion Therapeutics, INC. | $61.75 | 2021-2022 | |
| Smith+Nephew, INC. | $55.80 | 2021-2025 | Renasys |
| Amarin Pharma, INC. | $43.25 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $37.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $37.01 | 2022-2023 | Eliquis |
| Radius Health, INC. | $33.75 | 2025 | Tymlos |
| Dexcom, INC. | $33.22 | 2021-2024 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $22.02 | 2025 | Xyosted |
| Arbor Pharmaceuticals, INC. | $20.04 | 2021 | |
| Genentech USA, INC. | $18.46 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $16.14 | 2024 | Rexulti |
| Reprise Biomedical, INC. | $15.01 | 2025 | Mirotract |
| Allergan, INC. | $14.63 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Dorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.